After 1:5 Stock Split Zero Debt Stock To Mull Bonus Shares Next Week: Do You Own?

A small-cap pharmaceutical firm Remedium Lifecare trades API intermediates (KSMs & CRMs) as well as a range of other raw materials utilised in API trading. namely, Trimethyl Sulfoxonium Iodide (TMSI), Iodine, Grignard Reagent, Tellurium (IV) Oxide, Iodine, and Selenium Metal Powder. One of the largest portfolios of intermediates and active pharmaceutical ingredients (APIs) is provided by Remedium. The firm is a pharmaceutical one that operates in the product and service domains. The company's product business consists of trading and selling APIs and Intermediates to generic pharmaceutical companies in domestic and international markets, including those that are regulated. On Friday, the shares of Remedium Lifecare opened higher at Rs 106.50 apiece after the company declared that its Board of Directors is scheduled to meet next week to consider and approve bonus shares and financial results for the quarter and financial year ended 31st March 2024.

"Pursuant to Regulation 29 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, we hereby inform you that the meeting of the Board of Directors of the Company is scheduled to be held on Friday, May 10th 2024, inter alia to: 1. Consider and approve the Audited Financial Results for the quarter and Financial Year ended 31st March 2024. 2. Consider Recommendation and approval of the issue of Bonus Shares to the existing Equity Shareholders of the Company. 3. Consider any other matter with the approval of the Board," the company said in a regulatory filing on Thursday.

"Further, as per SEBI (Prohibition of Insider Trading) Regulations, 2015, and in terms of the Code of Conduct for prevention of Insider Trading in the Shares of Remedium Lifecare Limited, as informed to you vide our letter dated March 26th, 2024, the Trading Window has been closed from April 01st, 2024 and shall remain closed until 48 hours after the declaration of audited financial results for the quarter and Financial Year ended 31st March, 2024," informed Remedium Lifecare to the stock exchanges.

Remedium Lifecare is one of Dalal Street's multibagger stocks, having returned a whopping 18,758% over the previous five years and 5,687% over the previous three years. The stock has risen 71% over the last year, and so far in 2024, it has gained 6% year to date. The corporation announced its first-ever 1:5 stock split in 2024, with the record date being February 3, 2024. Remedium Lifecare is a debt-free company with a low P/E of 13.83, lower than its sector PE ratio of 77.45 and high ROE of 52.35% in the last fiscal, as per the data of Trendlyne.